US EditionLong-term gantenerumab Alzheimer's trial halted due to 'no regulatory path'
Summary by Medical Xpress
1 Articles
1 Articles
All
Left
Center
1
Right
Long-term gantenerumab Alzheimer's trial halted due to 'no regulatory path'
Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer's disease (DIAD). Gantenerumab was associated with serious safety concerns, including a high incidence of brain bleeding and swelling, possibly leading to an early study termination.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
